Vaccinia Virus Capping Enzyme - HYJ231
Vaccinia Virus Capping Enzyme Cat. No. HYJ231

Product Overview

The 5′ cap structure is essential for the stability and translation of eukaryotic mRNA. Hyasen Vaccinia Virus Capping Enzyme catalyzes the formation of a 5′ Cap 0 structure (m7GpppN) through its RNA triphosphatase, guanylyltransferase, and guanine methyltransferase activities. It is suitable for enzymatic capping of in vitro transcribed RNA and can be combined with mRNA Cap 2′-O-Methyltransferase for further conversion to Cap 1 RNA.

Components

Components2KU10KU100KU1000KU
Vaccinia Virus Capping Enzyme (10 U/μL)0.2 mL1 mL10 mL100 mL
10× Capping Buffer0.4 mL2×1mL2×10 mL2×100mL

Product Features

  • Post-IVT mRNA Capping: Supports enzymatic capping after RNA transcription.
  • Three Enzymatic Activities: Combines RNA triphosphatase, guanylyltransferase, and guanine methyltransferase functions.
  • Quality Controlled: Tested for residual RNase and DNA nuclease activities.

FAQ

Q1: What is Vaccinia Virus Capping Enzyme used for?

It is used to add a 5′ Cap 0 structure to RNA transcripts, supporting mRNA preparation for downstream translation-related applications.

Q2: Does Vaccinia Virus Capping Enzyme produce Cap 0 or Cap 1?

It produces Cap 0. An additional Cap 2′-O-Methyltransferase reaction is required to convert suitable Cap 0 RNA into Cap 1 RNA.

Q3: What are the recommended capping conditions?

Hyasen recommends incubation at 37°C for 30 minutes, using the supplied 10× Capping Buffer, GTP, and SAM.